Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07190248 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 20
- Study locations
NCT07190248 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 675 participants, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT07190248, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Calderasib
- BIOLOGICAL Pembrolizumab (+) Berahyaluronidase alfa
Study Locations (20)
Other
- Hospital Italiano de Cordoba ( Site 0308) - Córdoba
- CEMAIC ( Site 0309) - Córdoba
- IBCC - Núcleo de Pesquisa e Ensino ( Site 0417) - São Paulo
Buenos Aires
- Instituto Alexander Fleming ( Site 0311) - Ciudad Autónoma de Buenos Aires
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0300) - Mar del Plata
New South Wales
- Genesis Care- Campbelltown ( Site 2907) - Campbelltown
- Northern Beaches Hospital ( Site 2905) - Frenchs Forest
Queensland
- The Prince Charles Hospital ( Site 2903) - Brisbane
- Mater Hospital Brisbane ( Site 2906) - South Brisbane
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0503) - Santiago
- Bradfordhill ( Site 0501) - Santiago
Alabama
- Central Alabama Research ( Site 0108) - Birmingham
Connecticut
- Stamford Hospital ( Site 0126) - Stamford
Florida
- Mount Sinai Cancer Center ( Site 0137) - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2032-08-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07190248
The ClinicalTrials.gov registry entry for NCT07190248 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT07190248 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Buenos Aires, New South Wales.
Frequently Asked Questions
What is clinical trial NCT07190248 about?
NCT07190248 is a clinical study titled "A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)". Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderas...
What is the current status of trial NCT07190248?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2025-10-08. Estimated completion is 2032-08-06.
What conditions does trial NCT07190248 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT07190248?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Calderasib (DRUG), Pembrolizumab (+) Berahyaluronidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT07190248?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07190248 being conducted?
This trial has 20 study locations across Alabama, Connecticut, Florida, Maine, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.